Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder. In additional embodiments, these methods can be used to determine the lowest effective dosage of the therapeutic agent of use to treat the subject.
申请公布号
EP2972390(A1)
申请公布日期
2016.01.20
申请号
EP20140722428
申请日期
2014.03.13
申请人
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECTRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES;EMORY UNIVERSITY
发明人
HUIZING, MARJAN;GAHL, WILLIAM, A.;CARRILLO-CARRASCO, NURIA;HE, MIAO;LI, XUELI;JIANG, RONG